Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Antibodies, Neoplasm
and you are
between 1 and 21
years old
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

patients with progressive/relapsed solid tumors who failed first line therapy , will be treated biweekly with the anti PD1- Nivolumab. at least one month after treatment initiation low dose cyclophosphamide will be started . patients on trial will submit tissue and blood tests for whole exome an immune genomic signature. patients will also undergo repeated immunophenotype as part of follow up.

Provided treatments

  • Drug: Nivolumab,low dose cyclophosphamide
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02901145. The sponsor of the trial is Hadassah Medical Organization and it is looking for 30 volunteers for the current phase.
Official trial title:
A Phase I/II Clinical Trial of Nivolumab in Progressive/Relapsed Pediatric Solid Tumors